1. A case report about focal status epilepticus as first presentation in Alzheimer's disease: finding the culprit.
- Author
-
Devulder A, Vanderlinden G, Cleeren E, Goovaerts V, Theys T, Van Laere K, and Van Paesschen W
- Subjects
- Humans, Female, Middle Aged, Magnetic Resonance Imaging methods, Hippocampus diagnostic imaging, Hippocampus pathology, Alzheimer Disease complications, Alzheimer Disease diagnosis, Alzheimer Disease diagnostic imaging, Status Epilepticus diagnosis, Status Epilepticus etiology, Status Epilepticus diagnostic imaging, Positron-Emission Tomography methods, Electroencephalography methods
- Abstract
Background: Neuronal hyperexcitability has been proposed to play a key role in Alzheimer's disease (AD). Understanding the relation between this enhanced excitability and AD pathology could provide a window for therapeutic interventions. However epileptiform activity is often subclinical, hidden on scalp EEG and very challenging to assess with current diagnostic modalities., Case Presentation: A woman in her sixties presented with acute confusion. Despite a normal scalp electroencephalogram (EEG), magnetic resonance imaging (MRI) showed cytotoxic edema of the right mesial temporal lobe and hippocampal hypermetabolism was present on ([
18 F]-fluoro-2-deoxyglucose positron emission tomography (PET). Bilateral foramen ovale (FO) electrodes were placed to directly record mesial temporal activity and revealed continuous mesial temporal epileptic activity, while scalp EEG remained normal. After recovery, a new diagnosis of AD was established on cerebrospinal fluid. The lateralization of the epileptiform activity was congruent with the predominant side of tau pathology in the mesial temporal cortex on18 F-MK6240 PET. On follow-up MRI, two and five months later, the right hippocampus became atrophic., Conclusion: This case highlights the significant role of neuronal hyperexcitability in early AD pathogenesis and how shared mechanisms between AD and epilepsy can complicate clinical management., Competing Interests: Declarations. Ethics approval and consent to participate: Written informed consent was obtained for all procedures from the participant and caregiver. The study was approved by the Ethical Committee of University Hospitals Leuven (clinical.trials.gov NCT03617497). Consent for publication: Patient gave written informed consent for publication of the manuscript. Competing interests: K.V.L. has contract research through Leuven Research and Development with BMS, Cerevel and Janssen Pharmaceuticals and is advisory board member for 18F-MK6240 for Cerveau-Enigma. W.V.P. has grant for Toegepast Biomedisch Onderzoeks-Fonds voor Wetenschappelijk Onderzoek (FWO-TBM) (T000423N) and receives consulting fees from Angeline Pharma, UCB Pharma and Byteflies. The other authors have nothing to report., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF